VistaGen Therapeutics Inc Total Assets
VistaGen Therapeutics Inc total assets. Based on the latest financial reports, VistaGen Therapeutics Inc (VTGN) holds total assets worth $48.56 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see VistaGen Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of VistaGen Therapeutics Inc (2008–2026)
Total assets of VistaGen Therapeutics Inc from 2008 to 2026. This chart illustrates how VistaGen Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See VistaGen Therapeutics Inc stock quote for real-time trading data and today's change.
VistaGen Therapeutics Inc - Asset Composition Analysis
VistaGen Therapeutics Inc Total Assets Breakdown (March 2026)
VistaGen Therapeutics Inc total assets breakdown as of March 2026. VistaGen Therapeutics Inc's total assets of $48.56 Million consist of 96.7% current assets and 3.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2026)
This chart illustrates how VistaGen Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore VistaGen Therapeutics Inc (VTGN) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VistaGen Therapeutics Inc's current assets represent 96.7% of total assets in 2026, a decrease from 100.0% in 2008.
- Cash Position: Cash and equivalents constituted 63.4% of total assets in 2026, down from 100.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
VistaGen Therapeutics Inc Competitors by Total Assets
Key competitors of VistaGen Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
VistaGen Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.67 | 6.51 | 15.93 |
| Quick Ratio | 3.67 | 6.51 | 15.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $34.15 Million | $69.46 Million | $93.56 Million |
VistaGen Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between VistaGen Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -42.4% |
| Total Assets | $48.56 Million |
| Market Capitalization | $7.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values VistaGen Therapeutics Inc's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: VistaGen Therapeutics Inc's assets decreased by 42.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VistaGen Therapeutics Inc (2008–2026)
The table below shows the annual total assets of VistaGen Therapeutics Inc from 2008 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $48.56 Million | -42.42% |
| 2025-03-31 | $84.34 Million | -31.79% |
| 2024-03-31 | $123.65 Million | +486.34% |
| 2023-03-31 | $21.09 Million | -71.75% |
| 2022-03-31 | $74.64 Million | -31.07% |
| 2021-03-31 | $108.28 Million | +1775.88% |
| 2020-03-31 | $5.77 Million | -58.80% |
| 2019-03-31 | $14.01 Million | +24.24% |
| 2018-03-31 | $11.28 Million | +203.82% |
| 2017-03-31 | $3.71 Million | +275.05% |
| 2016-03-31 | $989.80K | +267.00% |
| 2015-03-31 | $269.70K | +2.28% |
| 2014-03-31 | $263.70K | -70.09% |
| 2013-03-31 | $881.50K | +158.05% |
| 2012-03-31 | $341.60K | +15427.27% |
| 2011-03-31 | $2.20K | +59.88% |
| 2010-03-31 | $1.38K | -94.03% |
| 2009-03-31 | $23.06K | +24173.68% |
| 2008-03-31 | $95.00 | -- |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more